Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.39 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 9/20 | 0.95 |
| ▸ | CD44 | P16070 | 2/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13441 | 0.98 | — | — | |
| Bromide SCHEMBL28557676 | 0.95 | PNMT (0.95) | PNMTCD44MAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5317536 | 0.93 | PNMT (0.91) | PNMTCD44MAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11178008 | 0.87 | PNMT (0.73) | PNMTCD44MAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11181806 | 0.86 | PNMT (0.72) | PNMTCD44MAOBDRD2DRD3 | |
| Acetic Acid SCHEMBL28560088 | 0.85 | PNMT (0.75) | PNMTCD44MAOB | |
| SCHEMBL3581219 | 0.84 | PNMT (0.76) | PNMTCD44MAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL1427992 | 0.84 | PNMT (0.69) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL997292 | 0.84 | PNMT (0.75) | PNMTCD44MAOBDRD2DRD3 | |
| SCHEMBL23142283 | 0.83 | PNMT (0.73) | PNMTCD44MAOBADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080798-A | Preparation method of 4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride | 杭州永太生物医药有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-117801612-A | Industrial water-based anticorrosive paint and preparation method thereof | 大庆市盛日石油技术开发有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-115521675-A | Industrial water-based heavy-duty anticorrosive paint and preparation method and application thereof | 大庆市盛日石油技术开发有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-112964794-B | Method for separating and detecting 4,5,6,7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride and related substances thereof | 武汉武药制药有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-112759575-B | Preparation method of clopidogrel hydrogen sulfate and intermediate N- (2-thienylethyl) methylamine thereof | 武汉武药制药有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-113881291-A | Industrial water-based heavy-duty anticorrosive paint | 大庆市盛日石油技术开发有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-109293569-B | Method for preparing formamide derivative through amine transfer reaction without participation of catalyst | 湘潭大学 | 2021-08-06 | — | — | CN | claimed |
| CN-112964794-A | Method for separating and detecting 4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride and related substances thereof | 武汉武药制药有限公司 | 2021-06-15 | — | — | CN | claimed |
| CN-112759575-A | Preparation method of clopidogrel hydrogen sulfate and intermediate N- (2-thienylethyl) methylene thereof | 武汉武药制药有限公司 | 2021-05-07 | — | — | CN | claimed |
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | claimed |
| EP-2084164-A2 | IMPROVED PROCESS FOR PREPARING CLOPIDOGREL | Teva Pharmaceutical Industries Ltd. (IL) | 2009-08-05 | — | — | EP | claimed |
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | claimed |
| US-20080287679-A1 | Process for preparing clopidogrel | TEVA PHARMACEUTICALS USA, INC. | 2008-11-20 | — | — | US | claimed |
| WO-2008130642-A2 | IMPROVED PROCESS FOR PREPARING CLOPIDOGREL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-30 | — | — | WO | claimed |
| EP-1848720-A1 | RAPID RESOLUTION PROCESS FOR CLOPIDOGREL BASE AND A PROCESS FOR PREPARATION OF CLOPIDOGREL BISULFATE POLYMORPH - FORM I | USV LIMITED (IN) | 2007-10-31 | — | — | EP | claimed |
| EP-1723141-A4 | INDUSTRIAL PROCESS FOR PREPARATION OF CLOPIDOGREL HYDROGEN SULPHATE | IPCA LAB LTD (IN) | 2007-10-10 | — | — | EP | claimed |
| EP-1723141-A2 | INDUSTRIAL PROCESS FOR PREPARATION OF CLOPIDOGREL HYDROGEN SULPHATE | IPCA Laboratories Limited (IN) | 2006-11-22 | — | — | EP | claimed |
| WO-2006087729-A1 | RAPID RESOLUTION PROCESS FOR CLOPIDOGREL BASE AND A PROCESS FOR PREPARATION OF CLOPIDOGREL BISULFATE POLYMORPH - FORM I | USV LIMITED (IN) | 2006-08-24 | — | — | WO | claimed |
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | USV LIMITED (IN) | 2006-04-06 | — | — | US | claimed |
| WO-2005104663-A2 | INDUSTRIAL PROCESS FOR PREPARATION OF CLOPIDOGREL HYDROGEN SULPHATE | IPCA LABORATORIES LIMITED (IN) | 2005-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | SRR, P2RY11, CYP2C19 | MAOB 354/4885ADRA2A 271/4885ADRA2B 160/4885 |
| US-20080287679-A1 | Process for preparing clopidogrel | P2RY6, P2RY12, P2RY11 | MAOB 613/4885ADRA2A 297/4885ADRA2B 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.